Randomized study of ACVBP [doxorubicin + cyclophosphamide + vindesine + bleomycin + prednisone] versus ACVBP plus rituximab in previously untreated patients aged from 18 to 65 years with low-risk localized diffuse large B-cell lymphoma (Age-Adjusted IPI = 0).

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Bleomycin; Cyclophosphamide; Doxorubicin; Prednisone; Vindesine
Indications Diffuse large B cell lymphoma
Focus Therapeutic Use

Most Recent Events

13 Mar 2017 Biomarkers information updated
12 Dec 2012 Interim results published in Annals of Oncology.
03 Mar 2011 Additional lead trial centers and investigators identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight